ASTRAZENECA PLC-SPONS ADR (AZN) Stock Price, Forecast & Analysis
NYSE:AZN • US0463531089
AZN Key Statistics, Chart & Performance
The current stock price of AZN is 208.45 USD. In the past month the price increased by 12.57%. In the past year, price increased by 36.76%.
AZN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to AZN. When comparing the yearly performance of all stocks, AZN is one of the better performing stocks in the market, outperforming 81.75% of all stocks.
AZN Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to AZN. While AZN belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
AZN Financial Highlights
Over the last trailing twelve months AZN reported a non-GAAP Earnings per Share(EPS) of 9.24. The EPS increased by 11.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 17.41% | ||
| ROA | 8.96% | ||
| ROE | 21.01% | ||
| Debt/Equity | 0.55 |
AZN Forecast & Estimates
34 analysts have analysed AZN and the average price target is 202.76 USD. This implies a price decrease of -2.73% is expected in the next year compared to the current price of 208.45.
For the next year, analysts expect an EPS growth of 15.32% and a revenue growth 6.85% for AZN
AZN Ownership
AZN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 31.34 | 966.197B | ||
| JNJ | JOHNSON & JOHNSON | 21.32 | 586.592B | ||
| MRK | MERCK & CO. INC. | 22.88 | 296.105B | ||
| PFE | PFIZER INC | 9.21 | 154.083B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.25 | 124.384B | ||
| ZTS | ZOETIS INC | 19.09 | 57.184B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.91 | 26.184B | ||
| VTRS | VIATRIS INC | 5.9 | 17.564B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 25.25 | 13.013B | ||
| AXSM | AXSOME THERAPEUTICS INC | 200.12 | 8.226B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About AZN
Company Profile
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The firm focuses on the discovery, development, and commercialization of prescription medicines. The firm operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. The company has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The firm distributes its products in over 125 countries.
Company Info
ASTRAZENECA PLC-SPONS ADR
1 Francis Crick Avenue, Cambridge Biomedical Campus
CAMBRIDGE CAMBRIDGESHIRE CB2 0AA GB
CEO: Pascal Soriot
Employees: 94300
Phone: 442037495000
ASTRAZENECA PLC-SPONS ADR / AZN FAQ
Can you describe the business of ASTRAZENECA PLC-SPONS ADR?
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The firm focuses on the discovery, development, and commercialization of prescription medicines. The firm operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. The company has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The firm distributes its products in over 125 countries.
What is the current price of AZN stock?
The current stock price of AZN is 208.45 USD. The price increased by 2.19% in the last trading session.
Does ASTRAZENECA PLC-SPONS ADR pay dividends?
ASTRAZENECA PLC-SPONS ADR (AZN) has a dividend yield of 1.6%. The yearly dividend amount is currently 3.21.
What is the ChartMill rating of ASTRAZENECA PLC-SPONS ADR stock?
AZN has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
How is the market expecting AZN stock to perform?
34 analysts have analysed AZN and the average price target is 202.76 USD. This implies a price decrease of -2.73% is expected in the next year compared to the current price of 208.45.
Is ASTRAZENECA PLC-SPONS ADR (AZN) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on AZN.
What is the expected growth for AZN stock?
The Revenue of ASTRAZENECA PLC-SPONS ADR (AZN) is expected to grow by 6.85% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.